MorphoSys AG

MOR

DE0006632003

Biotechnology & Medical Research

Real-time Estimate Tradegate Other stock markets 02:24:06 13/05/2024 pm IST			5-day change	1st Jan Change
67.08 ^EUR	+0.11%		+0.60%	+97.21%

06/05	MORPHOSYS : UBS reiterates its Neutral rating	ZD
30/04	European Equities Traded in the US as American Depositary Receipts Decline	MT

MORPHOSYS : Deutsche Bank reiterates its Neutral rating

December 15, 2023 at 06:04 pm IST

Initially Neutral on the company, Deutsche Bank's analyst Emmanuel Papadakis maintained his recommendation. The target price is unchanged at EUR 25.

Latest news about MorphoSys AG

MORPHOSYS : UBS reiterates its Neutral rating	06/05	ZD
European Equities Traded in the US as American Depositary Receipts Decline	30/04	MT
MorphoSys AG Reports Earnings Results for the First Quarter Ended March 31, 2024	30/04	CI
MORPHOSYS : UBS remains Neutral	30/04	ZD
Novartis target Morphosys multiplies losses - takeover schedule stands	30/04	DP
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Monday Trading	29/04	MT
Morphosys says takeover by Novartis on course after report of drug safety concern	29/04	RE
Health Care Slips on Risk Bias -- Health Care Roundup	12/04	DJ
Trending : Novartis Begins Tender Offer for MorphoSys Shares	12/04	DJ
Novartis: MorphoSys Board recommends tender offer	11/04	CF
MorphoSys Board Supports Norvartis' Buyout Offer as Tender Period Begins	11/04	MT
Morphosys management bodies recommend acceptance of Novartis takeover bid	11/04	DP
Novartis begins tender offer for cancer-focused MorphoSys	11/04	RE
Novartis Launches Tender Offer for Germany's MorphoSys	11/04	MT
Novartis initiates tender offer for MorphoSys	11/04	CF
Novartis begins tender offer for cancer-focused MorphoSys	11/04	RE
MorphoSys Gets US Antitrust Approval for Proposed Acquisition by Novartis	22/03	MT
Novartis' EUR2.7 Billion Purchase of MorphoSys Secures US Antitrust Clearance	22/03	MT
INDEX-MONITOR: Morphosys and Bilfinger in the MDax as of today - Dax unchanged	18/03	DP
MorphoSys AG(XTRA:MOR) added to Germany MDAX Index (Performance)	18/03	CI
MorphoSys AG(XTRA:MOR) dropped from Germany SDAX (Total Return) Index	15/03	CI
Morphosys sees no obstacle on its way under the Novartis umbrella	14/03	DP
Transcript : MorphoSys AG, 2023 Earnings Call, Mar 14, 2024	14/03
MorphoSys Q4 EPS, Revenue Decrease	14/03	MT
Morphosys with higher loss - takeover process by Novartis going according to plan	14/03	DP

MorphoSys AG is a global commercial-stage biopharmaceutical company based in Germany. The Company discovers, develops, and delivers cancer medicines to patients. It markets its proprietary medicine Monjuvi (tafasitamab-cxix) in the United States, a cancer immunotherapy treatment, used to treat patients in combination with lenalidomide with second and later lines of diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant. Tafasitamab is also being evaluated in a global clinical trial as a first line therapy for DLBCL. Two additional product candidates are in late and mid-stage clinical development in oncology indications: pelabresib, a small-molecule BET inhibitor, is studied as a treatment for myelofibrosis, a type of bone marrow cancer for which treatment options are limited; and CPI-0209, a second generation EZH2 inhibitor, is studied for treating hematological and solid tumors.

Sector

Biotechnology & Medical Research

Calendar

01/06/2024 - American Society of Clinical Oncology Annual Meeting - Abstract No #6502

More about the company

Income Statement Evolution

More financial data

Ratings for MorphoSys AG

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

67 EUR

Average target price

58.71 EUR

Spread / Average Target

-12.37%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MORPHOSYS AG	+97.21%	2.72B
MODERNA, INC.	+17.96%	44.96B
IQVIA HOLDINGS INC.	+1.17%	42.65B
LONZA GROUP AG	+46.23%	41.85B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research

MorphoSys AG

Equities

MOR

DE0006632003

Biotechnology & Medical Research

MORPHOSYS : Deutsche Bank reiterates its Neutral rating

Latest news about MorphoSys AG

Chart MorphoSys AG

Company Profile

Income Statement Evolution

Ratings for MorphoSys AG

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research